Growth potential Target IPA and its subsidiaries for collaboration on AI-driven biotherapeutic discovery platforms. Their ongoing investments in BioStrand HYFT, LENSai and intercompany SaaS/API deployments indicate a strong openness to partnerships that expand data processing, AI-driven drug discovery, and health data integration.

R&D to revenue Leverage IPA’s strategic shift from heavy R&D spend to revenue-generating assets from Talem and BioStrand. Propose solutions that accelerate conversion of research programs into commercial offerings, such as scalable labs, automation, and data analytics tools that support faster time-to-market.

Expanded capacity IPA is expanding laboratory space in Oss and upgrading capabilities with high-throughput platforms like Carterra LSA. This creates opportunities to supply advanced instrumentation, consumables, and service packages that support high-throughput antibody discovery and downstream development.

Data collaboration Strategic partnerships with InterSystems and PGxAI highlight a demand for health data processing, pharmacogenomics analytics, and health record data integration. Propose data management, interoperability, and AI model hosting solutions for health outcomes and assay data management.

AI-enabled services IPA’s adoption of LENSai and HYFT technologies signals appetite for AI-driven discovery platforms. Offer complementary AI optimization, model deployment, and cloud-scale analytics services to strengthen their end-to-end in silico and in vitro workflows.